

Oral treatment of AML with decitabine/cedazuridine combinations



STUDY OVERVIEW:

- These two studies investigated all-oral treatment combinations with decitabine/cedazuridine and other treatments for patients with AML
- An all-oral option aims to make treatment more convenient and needle-free

	Study 1	Study 2
What was studied? 	Decitabine/cedazuridine alone or combined with one of four targeted oral agents (venetoclax, gilteritinib, ivosidenib or enasidenib)	Decitabine/cedazuridine and venetoclax in people who cannot have intensive chemotherapy due to age or health conditions
Who participated? 	31 adults (average age 68 years old) with AML in remission took part in this phase 1b study	60 adults (average age 80 years) with newly diagnosed AML took part in this phase 2 study
How effective was treatment? 	Remission (no leukemia cells detectable in blood or bone marrow) lasted for an average of 22.4 months 59% still in remission after a year	67% improved with treatment and had no visible signs of leukemia in their blood or bone marrow (complete remission)
How safe was the treatment? 	Serious side effects: 98% Had low white blood cells (leukopenia)	Serious side effects: 10% had fever and low white blood cells (neutropenic fever)



WHAT DOES THIS MEAN FOR PATIENTS?

- These studies highlight the potential of **oral therapies** for people with AML, particularly those who cannot receive intensive chemotherapy
- By **combining convenient, at-home treatments** like decitabine/cedazuridine with targeted agents, patients may be able to:
 - **Stay in remission longer**
 - **Improve quality of life with needle-free therapies**
- While **side effects like low blood counts are common**, they can be managed with **supportive care**, such as antibiotics and dose adjustments
- These treatments are **still being studied**, and ongoing research will help confirm their long-term **safety and potential benefits**

*References: 1. Bazinet A, et al. Poster presented at the 66th ASH Annual Meeting and Exposition, San Diego, December 8, 2024. Abstract #2896.
2. Bazinet A, et al. Poster presented at the 66th ASH Annual Meeting and Exposition, San Diego, December 9, 2024. Abstract #4277.*